A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | T. Kadia | F. Ravandi | E. Jabbour | N. Daver | S. O'brien | N. Jain | N. Short | K. Sasaki | Paul B. Koller | M. Yilmaz | A. Bazarbachi | G. Issa | R. Garris | Maria R. Khouri | D. Thomas